Literature DB >> 15771695

Serum and urine Helicobacter pylori antibody titer after intravenous gamma-globulin treatment for Kawasaki disease and its clearance.

Toshiaki Shimizu1, Yukiko Yarita, Mitsuyoshi Suzuki, Ken Takahashi, Yoshikazu Ohtsuka, Satoru Nagata, Kaoru Obinata, Yuichiro Yamashiro.   

Abstract

BACKGROUND: It is not clear the effect of gamma-globulin therapy on results of enzyme-linked immunosorbent assays (ELISA) based on serum and urine for detection of Helicobacter pylori (H. pylori) antibodies, although the therapy can cause false-positive results in those assays.
METHODS: To examine the effect of intravenous gamma-globulin (IVIG) treatment on the results of ELISA based on serum and urine, levels of H. pylori IgG were measured in the serum and urine before and after IVIG therapy in 18 children with Kawasaki disease (KD) uninfected with H. pylori.
RESULTS: The serum and urine H. pylori IgG levels decreased time-dependently after the IVIG therapy and there were significant differences (P < 0.01) in the levels prior to therapy and at 7 days and 1 month after the therapy. The significant difference in the H. pylori IgG levels prior to therapy and 3 months after the therapy was observed in the serum but not in the urine.
CONCLUSION: The results suggest that gamma-globulin administration can cause false-positive results in ELISA based both on serum and urine for detection of H. pylori antibodies, and that the H. pylori antibodies cleared much more quickly from the urine than from the serum.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15771695     DOI: 10.1111/j.1442-200x.2005.02037.x

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  1 in total

1.  Effects of IVIg treatment on autoantibody testing in neurological patients: marked reduction in sensitivity but reliable specificity.

Authors:  Thomas Grüter; Anthonina Ott; Wolfgang Meyer; Sven Jarius; Markus Kinner; Jeremias Motte; Kalliopi Pitarokoili; Ralf Gold; Lars Komorowski; Ilya Ayzenberg
Journal:  J Neurol       Date:  2019-11-14       Impact factor: 4.849

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.